Table 4.
Antithrombotic therapy and thrombosis or occlusion outcomes
| Article | Demographics | Anticoagulant therapy | Antiplatelet therapy | Stent outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of study participants | Mean age | Anticoagulant | INR goal | Duration (m) | Off A/C at 6 months | Antiplatelet therapy | Duration of antiplatelet therapy (m) | Occlusion is acute phase | Occlusion in midterm (12 m) phase | # Patients with occlusion or VTE recurrence within 12 months | |
| Goldman (2017) | 6 | 17 | Variable but described (Fondaparinux, Enoxaparin, Warfarin) | Variable but delineated (6—lifelong) | 1/6 | No | No | 2 | 2 | ||
| Husman (2007) | 11 | 34 | Warfarin | 2‐3 | 6 | Yes | N | 1 | 1 | 2 | |
| Kim (2017) | 25 | 61 | Warfarin | 2‐3 | 6 | Yes | Aspirin and clopidogrel | 12 | 1 | No | 1 |
| Matsuda (2014) | 13 | 63 | Warfarin | 1.5‐2.5 | Variable but delineated (6—lifelong) | No | 1 | 1 | 2 | ||
| Roy (2017) | 6a | 48 | Warfarin | 2‐3 | “Long‐term” | N | No | No | 0 | ||
A/C, anticoagulation; INR, international normalized ratio; m, months; VTE, venous thromboembolism.
a
It is unclear the genders of the 6 patients who underwent stent placement in the Roy study. 7 patients identified, (6 female, 1 male), but 1 did not have stent placement, unclear which gender. That patient not included in this systematic review.